Welcome to our dedicated page for Twist Bioscience news (Ticker: TWST), a resource for investors and traders seeking the latest updates and insights on Twist Bioscience stock.
Twist Bioscience Corporation (NASDAQ: TWST) is a synthetic biology and biotechnology company whose news flow reflects its focus on synthetic DNA tools, silicon-based DNA synthesis and research-enabling technologies. Company announcements frequently describe Twist as a mid-cap growth and value biotech company serving customers in medicine, agriculture, industrial chemicals and defense, where its DNA-based products support research and development programs.
On this page, readers can follow TWST news related to product launches, collaborations, financial updates and corporate developments. Recent press releases have highlighted the launch of research-grade plasmid DNA preps for nucleic acid therapeutics research, including animal origin-free and transfection-grade options with specific quality attributes and target yields. Other announcements cover expanded collaborations, such as the Trinity Freestyle Fast Hybridization workflow developed with Element Biosciences for the AVITI sequencing platforms.
Investors and researchers can also track earnings-related news, including preliminary revenue updates, quarterly and full-year financial results, and associated conference calls and webcasts. Corporate governance and compensation updates, such as inducement equity grants under Nasdaq Listing Rule 5635(c)(4), appear in Twist’s news stream as well.
In addition, Twist publishes news on biosecurity and policy engagement, including participation in a Science paper examining biosecurity screening practices in AI-assisted protein design. Conference presentations at major healthcare and life science events are also regularly announced. For anyone following TWST stock or the evolution of synthetic DNA technologies, this news page provides a centralized view of Twist Bioscience’s public communications and key milestones.
Twist Bioscience Corporation (NASDAQ: TWST) has announced a collaboration with deepCDR, focused on advanced antibody discovery using deep learning algorithms. This partnership aims to enhance Twist's ability to generate large panels of fully human antibody sequences, utilizing new AI Hypermutated scFv libraries. The collaboration is expected to streamline preclinical development by reducing validation work. Twist's innovative silicon platform enables the manufacturing of high-quality synthetic DNA, which is crucial for various applications, including drug discovery and genomics.
Illumina Ventures has closed its second investment fund, raising
Twist Bioscience Corporation announces the availability of synthetic RNA reference controls for the latest SARS-CoV-2 variants, AY.1 and AY.2, enhancing the accuracy of diagnostic tests. The company now offers a total of 22 synthetic RNA controls targeting SARS-CoV-2 and 15 for respiratory viruses. This initiative demonstrates Twist's commitment to monitoring viral evolution and developing effective testing tools. The synthetic controls are used globally in various assays and are noted for their sequence verification and coverage of the full viral genome.
Twist Bioscience (NASDAQ: TWST) and Adicet Bio (NASDA: ACET) have announced a collaboration aimed at accelerating the discovery of gamma delta T cell therapies targeting five undisclosed cancer-related antigens. Twist will utilize its proprietary antibody discovery technologies to aid in engineering immune cells with novel chimeric antigen receptors (CARs), enhancing Adicet's pipeline. The agreement includes an upfront technology licensing fee, clinical and regulatory milestones, and product royalties, emphasizing the partnership's potential in advancing T cell therapies for cancer treatment.
Twist Bioscience Corporation (NASDAQ:TWST) has entered a research collaboration with Boehringer Ingelheim to discover therapeutic antibodies using Twist's proprietary antibody libraries. This partnership enables the identification and optimization of potential antibody candidates across multiple targets. Twist will receive an upfront payment for each program and could earn up to $710 million in milestone payments related to clinical and regulatory success. The collaboration highlights Twist’s capabilities in antibody development aimed at personalized treatments.
Twist Bioscience Corporation (NASDAQ:TWST) announced a collaboration with Boehringer Ingelheim to utilize Twist's proprietary antibody libraries for discovering therapeutic antibodies. The agreement allows for a wide range of disease targets and grants Boehringer Ingelheim exclusive rights to develop any resulting antibodies. Twist will receive upfront payments for each program and could earn up to $710 million in milestone payments. Both companies aim to create new, personalized treatments for patients.
Twist Bioscience Corporation (NASDAQ: TWST) announced that CEO Emily M. Leproust and CFO Jim Thorburn will present at the Baird 2021 Global Healthcare Conference on September 14 at 4:20 p.m. Eastern Time. This virtual event will be available for live streaming on the company's investor relations website and archived for 30 days post-event. Twist Bioscience specializes in high-quality synthetic DNA production using a proprietary silicon-based platform, serving multiple industries, including healthcare and agriculture.
Twist Bioscience Corporation (NASDAQ: TWST) announced that CFO Jim Thorburn and CCO Patrick Finn will host a fireside chat at the UBS Genomics 2.0 and Medtech Innovations Summit on August 11th at 2:00 p.m. P.T. in Laguna Beach, California. The event will be webcast live and available for replay for 30 days after the chat. Twist Bioscience is a leader in synthetic biology, utilizing its unique silicon-based platform to produce a variety of synthetic DNA products for healthcare, agriculture, and research sectors.
Twist Bioscience (TWST) reported strong third-quarter results for fiscal 2021, ending June 30, with total revenues of $35.0 million, a 65% increase year-over-year. Orders reached $39.1 million, up from $24.7 million in Q3 2020. Despite a net loss of $40.0 million, or $0.82 per share, the company increased its revenue guidance, driven by growth in DNA synthesis and NGS tools. Key developments included the acquisition of iGenomX and advancements in NGS workflows, supporting a rising customer base of approximately 1,800 clients.
Twist Bioscience Corporation (NASDAQ: TWST) has appointed Dr. Melissa Starovasnik to its board of directors. With nearly 30 years of experience in protein and antibody drug discovery, including significant roles at Genentech, Dr. Starovasnik is expected to provide valuable strategic guidance for Twist's biopharma expansion. CEO Emily M. Leproust highlighted her expertise as crucial for leveraging Twist's DNA platform to support a diverse customer base. Dr. Starovasnik aims to enhance collaboration with Twist's leadership to capitalize on biopharmaceutical opportunities and further strengthen the company's market position.